107 related articles for article (PubMed ID: 11337059)
41. The development of IL-2 conjugated liposomes for therapeutic purposes.
Konigsberg PJ; Godtel R; Kissel T; Richer LL
Biochim Biophys Acta; 1998 Mar; 1370(2):243-51. PubMed ID: 9545572
[TBL] [Abstract][Full Text] [Related]
42. The anionic boron cluster (B12H11SH)2- as a means to trigger release of liposome contents.
Gabel D; Awad D; Schaffran T; Radovan D; Dărăban D; Damian L; Winterhalter M; Karlsson G; Edwards K
ChemMedChem; 2007 Jan; 2(1):51-3. PubMed ID: 17154431
[No Abstract] [Full Text] [Related]
43. Application of galactose-modified liposomes as a potent antigen presenting cell targeted carrier for intranasal immunization.
Wang HW; Jiang PL; Lin SF; Lin HJ; Ou KL; Deng WP; Lee LW; Huang YY; Liang PH; Liu DZ
Acta Biomater; 2013 Mar; 9(3):5681-8. PubMed ID: 23159567
[TBL] [Abstract][Full Text] [Related]
44. Improved cytotoxicity of antitumor compounds deliverable by the LDL pathway.
Dubowchik GM; Firestone RA
Bioconjug Chem; 1995; 6(4):427-39. PubMed ID: 7578363
[TBL] [Abstract][Full Text] [Related]
45. Effects of fusogenic and DNA-binding amphiphilic compounds on the receptor-mediated gene transfer into hepatic cells by asialofetuin-labeled liposomes.
Hara T; Kuwasawa H; Aramaki Y; Takada S; Koike K; Ishidate K; Kato H; Tsuchiya S
Biochim Biophys Acta; 1996 Jan; 1278(1):51-8. PubMed ID: 8611607
[TBL] [Abstract][Full Text] [Related]
46. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery.
Lee RJ; Wang S; Turk MJ; Low PS
Biosci Rep; 1998 Apr; 18(2):69-78. PubMed ID: 9743475
[TBL] [Abstract][Full Text] [Related]
47. Nanohybrid magnetic liposome functionalized with hyaluronic acid for enhanced cellular uptake and near-infrared-triggered drug release.
Nguyen VD; Zheng S; Han J; Le VH; Park JO; Park S
Colloids Surf B Biointerfaces; 2017 Jun; 154():104-114. PubMed ID: 28329728
[TBL] [Abstract][Full Text] [Related]
48. Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells.
Morisco A; Accardo A; Tesauro D; Palumbo R; Benedetti E; Morelli G
Biopolymers; 2011; 96(1):88-96. PubMed ID: 20560147
[TBL] [Abstract][Full Text] [Related]
49. Receptor-mediated endocytosis of poly(acrylic acid)-conjugated liposomes by macrophages.
Fujiwara M; Baldeschwieler JD; Grubbs RH
Biochim Biophys Acta; 1996 Jan; 1278(1):59-67. PubMed ID: 8611608
[TBL] [Abstract][Full Text] [Related]
50. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
[TBL] [Abstract][Full Text] [Related]
51. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
52. Liposome uptake by cultured macrophages mediated by modified low-density lipoproteins.
Ivanov VO; Preobrazhensky SN; Tsibulsky VP; Babaev VR; Repin VS; Smirnov VN
Biochim Biophys Acta; 1985 Jul; 846(1):76-84. PubMed ID: 4016158
[TBL] [Abstract][Full Text] [Related]
53. Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia.
Sahebkar A; Badiee A; Hatamipour M; Ghayour-Mobarhan M; Jaafari MR
Colloids Surf B Biointerfaces; 2015 May; 129():71-8. PubMed ID: 25829129
[TBL] [Abstract][Full Text] [Related]
54. Polymer based pH-sensitive carriers as a means to improve the cytoplasmic delivery of drugs.
Roux E; Francis M; Winnik FM; Leroux JC
Int J Pharm; 2002 Aug; 242(1-2):25-36. PubMed ID: 12176222
[TBL] [Abstract][Full Text] [Related]
55. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
56. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
Goren D; Horowitz AT; Zalipsky S; Woodle MC; Yarden Y; Gabizon A
Br J Cancer; 1996 Dec; 74(11):1749-56. PubMed ID: 8956788
[TBL] [Abstract][Full Text] [Related]
57. In vitro drug delivery mediated by ecto-NAD+-glycohydrolase ligand-targeted liposomes.
Salord J; Schuber F
Biochim Biophys Acta; 1988 Sep; 971(2):197-206. PubMed ID: 3167100
[TBL] [Abstract][Full Text] [Related]
58. Liposomes Containing Lipid-Soluble Zn(II)-Bis-dipicolylamine Derivatives Show Potential To Be Targeted to Phosphatidylserine on the Surface of Cancer Cells.
Ayesa U; Gray BD; Pak KY; Chong PL
Mol Pharm; 2017 Jan; 14(1):147-156. PubMed ID: 28043132
[TBL] [Abstract][Full Text] [Related]
59. Characterization of the interaction between liposomal formulations and Pseudomonas aeruginosa.
Jia Y; Joly H; Omri A
J Liposome Res; 2010 Jun; 20(2):134-46. PubMed ID: 19831502
[TBL] [Abstract][Full Text] [Related]
60. Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines.
Bergers JJ; Den Otter W; Dullens HF; Kerkvliet CT; Crommelin DJ
Pharm Res; 1993 Dec; 10(12):1715-21. PubMed ID: 8302756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
